NDAC, Pulmonary-Allergy to review Rx rhinitis switch candidates.
This article was originally published in The Tan Sheet
Executive Summary
VANCENASE AQ AND NASALCROM Rx-TO-OTC SWITCHES TO BE REVIEWED BY NDAC and FDA's Pulmonary-Allergy Drugs Advisory Committee on October 10-11 as treatments for seasonal allergic rhinitis. Schering-Plough is seeking to switch Vancenase AQ nasal inhaler, which contains beclomethasone dipropionate, an anti-inflammatory steroid. Johnson & Johnson's McNeil Consumer is sponsoring the Nasalcrom (cromolyn sodium) switch; prescription Nasalcrom is manufactured and sold by Fisons. The two products would be the first inhaled anti-inflammatory agents to be switched to over-the-counter status.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning